Four things the Mounjaro® label makes clear
The short version, from the Mounjaro® prescribing information, revised 08/2026.
Nausea and diarrhea lead the list
In the placebo-controlled trials in adults with type 2 diabetes, nausea was reported by 12% to 18% of people on Mounjaro® compared with 4% on placebo. Diarrhea was reported by 12% to 17%, compared with 9% on placebo.
Stomach effects rise with the dose
Any stomach side effect was reported by 37.1%, 39.6% and 43.6% of people across the three doses studied, compared with 20.4% on placebo. The higher the dose in the trials, the more often these effects showed up.
The label lists serious risks too
The label carries a boxed warning for thyroid C-cell tumors and lists pancreatitis, low blood sugar with insulin or a sulfonylurea, kidney injury, gallbladder disease and allergic reactions. Each one is explained further down this page.
Common effects in the type 2 diabetes trials
The first seven rows are the label's Table 1: side effects reported by at least 5% of people on Mounjaro®, and more often than on placebo, in the pooled placebo-controlled trials in adults with type 2 diabetes. The burping row comes from the label's text on the same trials. The doses in the column headings are the label's trial arms, not a recommendation.
| Side effect | Placebo | Mounjaro® 5 mg | Mounjaro® 10 mg | Mounjaro® 15 mg |
|---|---|---|---|---|
| Nausea | 4% | 12% | 15% | 18% |
| Diarrhea | 9% | 12% | 13% | 17% |
| Decreased appetite | 1% | 5% | 10% | 11% |
| Vomiting | 2% | 5% | 5% | 9% |
| Constipation | 1% | 6% | 6% | 7% |
| Indigestion (dyspepsia) | 3% | 8% | 8% | 5% |
| Stomach pain | 4% | 6% | 5% | 5% |
| Burping (eructation) | 0.4% | 3.0% | 2.5% | 3.3% |
Nausea and vomiting
Nausea was reported by 12%, 15% and 18% of people at the three doses studied, versus 4% on placebo. Vomiting was reported by 5%, 5% and 9%, versus 2% on placebo.
Diarrhea and constipation
Diarrhea was reported by 12% to 17% of people on Mounjaro® and by 9% on placebo. Constipation was reported by 6% to 7%, compared with 1% on placebo.
Lower appetite
Decreased appetite was reported by 5% to 11% of people on Mounjaro® versus 1% on placebo. Eating less is part of how the medicine works, and the label counts it as a common effect.
Indigestion, stomach pain and burping
Indigestion was reported by 5% to 8% and stomach pain by 5% to 6%, compared with 3% and 4% on placebo. Burping, listed as eructation, was reported by 2.5% to 3.3% versus 0.4%, and gas and reflux were also more frequent than on placebo. More on the smell question in sulfur burps on a GLP-1.
Injection site reactions and heart rate
Injection site reactions were reported by 3.2% of people on Mounjaro® compared with 0.4% on placebo (see GLP-1 injection site reactions). Average heart rate rose by 2 to 4 beats per minute, compared with 1 beat per minute on placebo.
Serious warnings on the Mounjaro® label
These events are uncommon, but they are why a new or unusual symptom should not always be put down to the medicine.
Boxed warning: thyroid C-cell tumors
Tirzepatide caused thyroid C-cell tumors in rats, and it is not known whether Mounjaro® does this in people. Anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN 2 should not use it. A lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath should be reported to your prescriber.
Pancreatitis
In clinical studies, acute pancreatitis was confirmed in 13 people on Mounjaro®, a rate of 0.23 per 100 years of exposure, versus 0.11 in the comparison groups. The label describes severe stomach pain that may spread to the back, with or without vomiting, as the sign to act on.
Low blood sugar with other diabetes medicines
The risk of low blood sugar goes up when Mounjaro® is used with insulin or a sulfonylurea. In the trial that added Mounjaro® to basal insulin, blood sugar below 54 mg/dL was reported by 14% to 19% of people, compared with 13% on placebo.
Kidney injury, gallbladder disease and allergic reactions
Fluid loss from vomiting or diarrhea can lead to acute kidney injury, which the label lists as a warning. Gallbladder disease was reported by 0.6% of people on Mounjaro® versus none on placebo, and serious allergic reactions such as anaphylaxis have been reported.
Eye changes, anesthesia, pregnancy and birth control pills
People with a history of diabetic retinopathy should be monitored for changes, and the label lists a risk of food or liquid entering the lungs during anesthesia or deep sedation. Based on animal studies, the label says Mounjaro® may cause harm to an unborn baby, so tell your prescriber if you are pregnant or planning to be.
Mounjaro® can make birth control pills less reliable, so the label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Talk to your prescriber about which method fits you.
When to get help
This list follows the warnings and Medication Guide in the Mounjaro® label. It is not a complete list and it is not medical advice: if something feels wrong, call.
Emergency care
Swelling of the face, lips, tongue or throat, trouble breathing, or a severe rash are signs of a serious allergic reaction and need emergency help. Severe stomach pain that does not go away, with or without vomiting, also needs urgent attention.
Call your prescriber
Contact your prescriber about any of these:
- Nausea, vomiting or diarrhea that is severe or will not go away, or signs of dehydration.
- Pain in the upper stomach, fever, yellowing of the skin or eyes, or clay-colored stools, which can be gallbladder signs.
- Shakiness, sweating, dizziness, a fast heartbeat, hunger, headache, blurred vision, confusion or irritability, which can mean low blood sugar, especially with insulin or a sulfonylurea.
- Any change in your vision, if you have type 2 diabetes.
- A lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
Before surgery or sedation
Tell your care team you take Mounjaro® before any planned surgery or procedure that uses anesthesia or deep sedation. The label asks patients to share this because slower stomach emptying can affect these procedures.
Questions about your dose
Questions about your dose, your schedule or a missed injection go to your prescriber, and your label has the official missed-dose instructions (our missed GLP-1 dose guide explains where to find them). This page shares label facts only and does not give dosing advice.
How to report a side effect
The label gives two contacts for reporting a suspected side effect: Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979), or the FDA's MedWatch program at 1-800-FDA-1088.
Why the first weeks and each step-up feel different
Knowing why an effect happens helps you describe it to your prescriber. Every point here comes from the label.
Food leaves the stomach more slowly
The label states that Mounjaro® delays gastric emptying. Food staying in the stomach longer is linked with fullness, nausea and indigestion.
Dose increases are when effects peak
The label's schedule starts at 2.5 mg once weekly, with 2.5 mg increases after at least 4 weeks on a dose, as the prescriber directs. That is the label's schedule, not a plan for you: your prescriber sets yours. Most nausea, vomiting and diarrhea in the trials showed up during these increases and eased over time.
Each weekly shot lasts for days
The label gives an elimination half-life of about 5 days, so each injection stays active through much of the week. That helps explain why some people notice their symptoms follow a pattern after shot day. The tirzepatide half-life calculator shows what a 5-day half-life looks like.
Children and teens saw more vomiting
Mounjaro® is also approved for children 10 and older with type 2 diabetes. In that trial, vomiting was reported by 12% to 16% and stomach pain by 15% to 22% of young patients, compared with 3% and 9% on placebo.
From the makers of this guide
Track how you feel week to week
The label gives trial averages. Your prescriber needs your version: which symptoms, how strong, and how they fall around shot day.
- 01
Built-in symptoms, each with a severity
The side-effect tracker has built-in GLP-1 symptoms grouped by area, such as injection site, digestive and head and nerves, plus your own, each saved by day with how severe it was. A short daily check-in asks about food noise, side effects and mood, and you can add questions such as energy and sleep.
- 02
Symptoms beside your shot history
Your side-effect trend chart sits on the Dose tab beside your Mounjaro® shot history, so nausea that shows up two days after every shot, or after a step-up, is easy to point to.
- 03
An estimated medication level
An estimated level chart on the same tab shows how your logged doses rise and fall across the week, which gives you something concrete to discuss with your prescriber.
- 04
What you ate on rough days
Log meals by photo scan, barcode or search in Nutrition, then look back at rougher days to notice which foods sat well and which did not.
Key takeaways
- Nausea was reported by 12% to 18% of adults on Mounjaro® in the type 2 diabetes trials, versus 4% on placebo.
- Stomach effects rose with the dose and clustered during dose increases, then decreased over time.
- 3.0% to 6.6% stopped Mounjaro® because of stomach effects, versus 0.4% on placebo.
- Mounjaro® carries the boxed thyroid C-cell tumor warning; low blood sugar risk rises with insulin or a sulfonylurea.
- Dose, schedule and missed-dose questions belong with your prescriber and your label.
Bring your side effects, not just a memory of them.
Pep AI logs your Mounjaro® shots, symptoms with severity, meals and weight, and makes a PDF of your doses, sites, weight and meal totals. Download Pep AI on iPhone or Android.
Frequently asked questions
Keep reading
Sources
This page summarizes the Mounjaro® prescribing information (revised 08/2026). It is general information, not medical advice, and does not replace your prescriber or pharmacist. Pep AI is not affiliated with or endorsed by Eli Lilly and Company. If a symptom is severe, getting worse or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026